CD19 and metabolic dysfunction-associated steatotic liver disease: Moreover, comparison with those in the NAFLD plus one specific comorbidity group, the lymphocytes counts and percentages, CD3+ counts and percentages, CD19+ counts and percentages, CD56+ counts and percentages, CD3+CD4+ counts and percentages, CD3+CD8+ counts and percentages, and the ratios of CD3+CD4+ to CD3+CD8+ (Figures 10A–H, 11A–E), were significantly decreased in the NAFLD plus two or more specific comorbidity group (P all <0.05).